GREY:ATBPF - Post by User
Comment by
nozzpackon Aug 04, 2021 10:47am
323 Views
Post# 33648030
RE:Brookline Capital - BUY Rating for ATE at $9 yesterday
RE:Brookline Capital - BUY Rating for ATE at $9 yesterday It seems that ATE 346 has been going through clinical trials for over a decade, which is quite a long time to not have the safety issue nailed down.
Its not all adding up why it has taken so long to verify an obvious benefit from a simple drug.
More and more lately, we have been finding that clinical trials contain fake data just to keep their investors on the hook.
I am not saying thats the case here but to have been developing this drug for over a decade and to not have cleared its safety profile seems like a red flag.
If this is the case, all of itsmain pipeline drugs are also at risk for clinical failure.
I would stay away until the dust settles here.